Experienced in Gastric Dysmotility

Dr. Michael J. Mccartney

Internal Medicine
Medical Care Of Boston Management Corporation
464 Hillside Ave, Suite 304, 
Needham, MA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Experienced in Gastric Dysmotility
Medical Care Of Boston Management Corporation
464 Hillside Ave, Suite 304, 
Needham, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Michael Mccartney is a primary care provider, practicing in Internal Medicine in Needham, Massachusetts. Dr. Mccartney is rated as an Experienced provider by MediFind in the treatment of Gastric Dysmotility. His top areas of expertise are Gastroesophageal Reflux Disease (GERD), Urinary Tract Infection in Children, Urinary Tract Infection (UTI), Type 2 Diabetes (T2D), and Endoscopy. Dr. Mccartney is currently accepting new patients.

His clinical research consists of participating in 30 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Internal Medicine
Licenses
Internal Medicine in MA
Hospital Affiliations
Lahey Hospital & Medical Center, Burlington
Anna Jaques Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

MEDICAL CARE OF BOSTON MANAGEMENT CORPORATION
464 Hillside Ave, Suite 304, Needham, MA 02494

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

24 Clinical Trials

A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
Enrollment Status: Recruiting
Publish Date: June 25, 2025
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: September 22, 2025
Intervention Type: Drug
Study Drug: Simufilam
Study Phase: Phase 3
The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
Enrollment Status: Completed
Publish Date: August 24, 2025
Intervention Type: Drug
Study Drugs: Tirzepatide, Dulaglutide
Study Phase: Phase 3
Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: July 28, 2025
Intervention Type: Drug
Study Drug: LY3372689
Study Phase: Phase 2
Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)
Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)
Enrollment Status: Completed
Publish Date: July 24, 2025
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Osteoarthritis Pain
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Osteoarthritis Pain
Enrollment Status: Completed
Publish Date: July 17, 2024
Intervention Type: Drug
Study Drug: LY3526318
Study Phase: Phase 2
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for Maintenance of Weight Loss in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-4)
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for Maintenance of Weight Loss in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-4)
Enrollment Status: Completed
Publish Date: May 22, 2024
Intervention Type: Other, Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Chronic Low Back Pain
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Chronic Low Back Pain
Enrollment Status: Completed
Publish Date: November 30, 2023
Intervention Type: Drug
Study Drug: LY3016859
Study Phase: Phase 2
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Diabetic Peripheral Neuropathic Pain
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Diabetic Peripheral Neuropathic Pain
Enrollment Status: Completed
Publish Date: November 22, 2023
Intervention Type: Drug
Study Drug: LY3526318
Study Phase: Phase 2
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Diabetic Peripheral Neuropathic Pain
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Diabetic Peripheral Neuropathic Pain
Enrollment Status: Completed
Publish Date: November 14, 2023
Intervention Type: Drug
Study Drug: LY3016859
Study Phase: Phase 2
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Osteoarthritis
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Osteoarthritis
Enrollment Status: Completed
Publish Date: November 14, 2023
Intervention Type: Drug
Study Drug: LY3016859
Study Phase: Phase 2
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Osteoarthritis Pain
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Osteoarthritis Pain
Enrollment Status: Completed
Publish Date: November 02, 2023
Intervention Type: Drug
Study Drug: LY3556050
Study Phase: Phase 2
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Diabetic Peripheral Neuropathic Pain
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Diabetic Peripheral Neuropathic Pain
Enrollment Status: Terminated
Publish Date: November 02, 2023
Intervention Type: Drug
Study Drug: LY3556050
Study Phase: Phase 2
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Chronic Low Back Pain
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Chronic Low Back Pain
Enrollment Status: Completed
Publish Date: November 02, 2023
Intervention Type: Drug
Study Drug: LY3556050
Study Phase: Phase 2
Randomized Placebo-controlled Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Chronic Low Back Pain
Randomized Placebo-controlled Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Chronic Low Back Pain
Enrollment Status: Completed
Publish Date: October 05, 2023
Intervention Type: Drug
Study Drug: LY3526318
Study Phase: Phase 2
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drug: BIIB092
Study Phase: Phase 2
Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: October 13, 2022
Intervention Type: Drug
Study Drug: LY3002813
Study Phase: Phase 2
A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of Tirzepatide Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of Tirzepatide Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
Enrollment Status: Completed
Publish Date: February 14, 2022
Intervention Type: Drug
Study Drugs: Tirzepatide, Semaglutide
Study Phase: Phase 3
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: September 02, 2021
Intervention Type: Drug
Study Phase: Phase 3
AMPOWER A Single-arm, Phase III, Open Label, Multi-center, Study in Women Aged 18-35 Years of the Contraceptive Efficacy and Safety of Phexxi™ (Previously Referred to as AMPHORA®) Contraceptive Vaginal Gel
AMPOWER A Single-arm, Phase III, Open Label, Multi-center, Study in Women Aged 18-35 Years of the Contraceptive Efficacy and Safety of Phexxi™ (Previously Referred to as AMPHORA®) Contraceptive Vaginal Gel
Enrollment Status: Completed
Publish Date: September 17, 2020
Intervention Type: Drug
Study Phase: Phase 3
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Enrollment Status: Terminated
Publish Date: December 03, 2019
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: October 10, 2019
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2, Double-Blind, Placebo-Controlled, 18-Week Trial of Investigational Dulaglutide Doses Versus Placebo in Patients With Type 2 Diabetes on Metformin Monotherapy
A Phase 2, Double-Blind, Placebo-Controlled, 18-Week Trial of Investigational Dulaglutide Doses Versus Placebo in Patients With Type 2 Diabetes on Metformin Monotherapy
Enrollment Status: Completed
Publish Date: September 23, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Study of Once-Weekly LY3298176 Compared With Placebo and Dulaglutide in Patients With Type 2 Diabetes Mellitus
A Phase 2 Study of Once-Weekly LY3298176 Compared With Placebo and Dulaglutide in Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: August 20, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 23 Less Clinical Trials
Similar Doctors
Distinguished in Gastric Dysmotility
Dr. Raju Singla
Internal Medicine
Distinguished in Gastric Dysmotility
Dr. Raju Singla
Internal Medicine

Prima Care, PC

277 Pleasant St, 
Fall River, MA 
 (41.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Raju Singla is a primary care provider, practicing in Internal Medicine in Fall River, Massachusetts. Dr. Singla is rated as a Distinguished provider by MediFind in the treatment of Gastric Dysmotility. Her top areas of expertise are Pneumonia, Necrosis, Gastroparesis, Endoscopy, and Ureteroscopy. Dr. Singla is currently accepting new patients.

Advanced in Gastric Dysmotility
Dr. Jaiganesh Dorai
Internal Medicine
Advanced in Gastric Dysmotility
Dr. Jaiganesh Dorai
Internal Medicine

Prima Care, PC

67 Slade's Ferry Boulevard, 
Somerset, MA 
 (39.3 miles away)
508-676-3292
Languages Spoken:
English
See accepted insurances

Jaiganesh Dorai is a primary care provider, practicing in Internal Medicine in Somerset, Massachusetts. Dr. Dorai is rated as an Advanced provider by MediFind in the treatment of Gastric Dysmotility. His top areas of expertise are Gastroparesis, Heart Attack, Gastric Dysmotility, Endoscopy, and Gastrostomy.

Advanced in Gastric Dysmotility
Dr. Shanjin Cao
Internal Medicine
Advanced in Gastric Dysmotility
Dr. Shanjin Cao
Internal Medicine

Prima Care, PC

277 Pleasant St, 
Fall River, MA 
 (41.1 miles away)
508-676-3292
Languages Spoken:
English
See accepted insurances

Shanjin Cao is a primary care provider, practicing in Internal Medicine in Fall River, Massachusetts. Dr. Cao is rated as an Advanced provider by MediFind in the treatment of Gastric Dysmotility. His top areas of expertise are Gastroparesis, Gastric Dysmotility, Lung Metastases, Colonoscopy, and Endoscopy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mccartney's expertise for a condition
ConditionClose
    View All 11 Advanced Conditions
    View All 132 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile